Gene upregulated in cancers of the prostate

• US 6,893,818 B1
• Filed: 10/26/2000
• Issued: 05/17/2005
• Est. Priority Date: 10/28/1999
• Status: Expired due to Fees

• Current Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Original Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Inventors: Raitano, Arthur B., Afar, Daniel E. H., Jakobovits, Aya, Hubert, Rene S., Mitchell, Steve Chappell
• Primary Examiner(s): Ungar, Susan
• Assistant Examiner(s): DAVIS, MINH TAM B
• Application Number:
  US09/697,206
• Time in Patent Office: 1,664 Days
• Field of Search: 435/6, 435/91.1, 435/91.2, 435/94, 536/23.1, 536/24.3, 536/24.31, 536/24.33, 536/23.5
• US Class Current: 435/6.14
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12N 2799/026 where the vector is derived from a baculovirus
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a novel protein designated 20P2H8 which shares homology with several heterogenous nuclear ribonucleoproteins (hnRNPs). A full length approximately 3600 bp 20P2H8 cDNA (SEQ ID NO: 10, encoding a 517 amino acid open reading frame (SEQ ID NO: 2), is provided herein.

Claims

1. A method of diagnosing the presence of cancer in an individual comprising:

(a) determining the level of 20P2148 (SEQ ID NO;

     1) mRNA expression in a test sample obtained from the individual; and

(b) comparing the level so determined to the level of 20P2118 (SEQ ID NO;

     1) mRNA expression in a known normal tissue sample of the same tissue type as the test sample,

wherein elevated 20132118 (SEQ ID NO;

     1) mRNA expression in the test sample relative to the normal tissue sample is diagnostic of the presence of cancer, and wherein the 20P2118 mRNA expression is determined utilizing SEQ ID NO;

1 as a probe.